• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

Narcolepsy Drugs Market Asia Pacific Anticipating Rapid Growth

September 21, 2021 by admin

What is Narcolepsy?

Narcolepsy is quite different from other sleep disorders. Insomnia, restless leg, and other disorders disrupt circadian rhythms and may cause sleep deprivation.

People with narcolepsy, however, experience changes to REM sleep. They may also experience associated conditions including sleep paralysis, sleep-related hallucinations, and the co-occurrence of other sleep disorders including sleep apnea and disrupted sleep.

Cataplexy is also strongly associated with narcolepsy. This sudden onset of muscle weakness is present in Type 1 narcolepsy and absent in Type 2.

An article in BioSpace from TMR Research looked at the market for narcolepsy drugs and the anticipation of rapid growth through 2028. Unlike CPAP for sleep apnea, there is no standard treatment for narcolepsy. 

Advances in sleep medicine are leading to more research and development of treatment options for this complex sleep disorder.

Narcolepsy Drugs Market

Common drug treatments for narcolepsy include third-line use of stimulants to combat the daytime sleepiness that plagues narcolepsy sufferers. 

Driving the market for narcolepsy treatments is the increasing awareness of the global prevalence and severity of narcolepsy and other sleep disorders. Underdiagnosed and undertreated, narcolepsy is a serious disorder garnering significant scientific and pharmaceutical interest.

According to the article, the high prevalence of sleep disorders in the Asia Pacific market, along with recognition of the need for treatment, is increasing demand in the region. 

Trends

Previous therapies for narcolepsy addressed symptoms, particularly daytime sleepiness. Those studies continue, along with the development of new stimulant drugs. 

Increasingly, researchers and drug companies are looking at drugs that address the cause of cataplexy, a serious and potentially dangerous part of narcolepsy. The goal of these drugs is to target the hormone depletion that leads to cataplexy. 

Orexin (hypocretin) is a hormone shown to be depleted in individuals with cataplexy. Directly addressing that depletion is a promising area of study and may lead to significant new drug developments.

Developments

Increasing numbers of U.S. FDA approvals are stimulating the market for narcolepsy drugs. Currently in the pipeline are drugs that combat daytime sleepiness and the cause of cataplexy.

Solriamfetol, a drug from Jazz Pharmaceuticals, is FDA approved for treating the excessive daytime sleepiness in adults that characterizes narcolepsy. 

The article points out that favorable regulatory action is likely to get new narcolepsy drugs to market sooner and spur the development of additional therapeutics.

Conclusions

Narcolepsy is receiving heightened attention worldwide. The potential to address the root cause of cataplexy, one of the most traumatic and dangerous symptoms, has spurred greater research and development.

The growing demand for effective treatments for narcolepsy indicates an expanding Asia Pacific market with significant potential for growth through 2028. Regulatory successes of several drugs in the U.S. may inspire the development of new narcolepsy treatments to meet that demand. 

 

Sources:

https://www.biospace.com/article/narcolepsy-drugs-market-asia-pacific-has-shown-large-potential-and-is-anticipated-to-rise-at-rapid-growth-rate-to-2028/

https://www.tmrresearch.com/narcolepsy-drugs-market

https://www.sleepfoundation.org/physical-health/cataplexy

https://www.sleepfoundation.org/narcolepsy

Filed Under: Blog Tagged With: narcolepsy

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy